The final, formatted version of the article will be published soon.
REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1459057
This article is part of the Research Topic Multi-omics Application in Exploring Potential Biomarkers Targeting Resistance of Anti-Cancer Drugs View all 15 articles
Cell Cycle Checkpoint Revolution: Targeted Therapies in the Fight Against Malignant Tumors
Provisionally accepted- 1 Second Affiliated Hospital of University of South China, Hengyang, China
- 2 Zhuzhou Central Hospital, Zhuzhou, Hunan, China
Malignant tumors are among the most important causes of death worldwide. The pathogenesis of malignant tumors is complex and has not been fully elucidated. Studies have shown that the pathogenesis of malignant tumors is related to abnormal cell cycle progression. The expression levels of cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors and the function of cell cycle checkpoints determine whether the cell cycle can proceed smoothly. Cell cycle-targeting drugs have the advantages of specificity, low toxicity and side effects, and reduced drug resistance. Identifying drugs that target the cell cycle and applying them in clinical treatment will promote the development of chemotherapy for malignant tumors. This article aims to review the targeted drugs against the cell cycle and their mechanism of action.
Keywords: Malignant tumor, Cell Cycle, cell cycle checkpoint, cyclin, cyclin-dependent kinase, Chemotherapeutic drugs
Received: 03 Jul 2024; Accepted: 16 Sep 2024.
Copyright: © 2024 Song, Liu, Tang, Zhong, Zeng, Zhang, Zhou, Zhou, Cao, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jue Liu, Second Affiliated Hospital of University of South China, Hengyang, China
Xing Tang, Zhuzhou Central Hospital, Zhuzhou, Hunan, China
Jie Zhong, Second Affiliated Hospital of University of South China, Hengyang, China
Yuhuan Zeng, Second Affiliated Hospital of University of South China, Hengyang, China
Xiaodi Zhang, Second Affiliated Hospital of University of South China, Hengyang, China
Jianbin Zhou, Second Affiliated Hospital of University of South China, Hengyang, China
Qunfeng Zhang, Second Affiliated Hospital of University of South China, Hengyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.